ACell, Inc. Share Price

Equities

ACLL

US00444J1025

Medical Equipment, Supplies & Distribution

Delayed Nasdaq 5-day change 1st Jan Change
- USD -.--% Intraday chart for ACell, Inc. -.--% -.--%
Sales 2018 89.22M 7.14B Sales 2019 101M 8.07B Capitalization 340M 27.23B
Net income 2018 -3M -240M Net income 2019 1M 80.05M EV / Sales 2018 * -
Net cash position 2018 * - 0 Net cash position 2019 * - 0 EV / Sales 2019 * -
P/E ratio 2018 *
-
P/E ratio 2019 *
-
Employees -
Yield 2018 *
-
Yield 2019 *
-
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
Integra LifeSciences Holdings Corporation completed the acquisition of ACell, Inc for approximately $410 million. CI
ACell, Inc. Announces CE Mark Approval CI
Integra LifeSciences Holdings Corporation entered into a definitive agreement to acquire ACell, Inc. for $400 million. CI
ACell, Inc. has withdrawn its IPO in the amount of $80 million. CI
ACell, Inc. has filed an IPO in the amount of $86.25 million. CI
ACell, Inc. Announces Launch of their New Product, Gentrix Hiatal at the 2019 Society of Laparoendoscopic Surgeons Minimally Invasive Surgery Week 2019 in New Orleans, Louisiana CI
ACell, Inc. and Southmedic Announce Canadian Launch of Gentrix Surgical Matrix Family of Products CI
ACell, Inc. Enters into Exclusive Long-Term Product Supply and Distribution Agreement with First Horizon, LLC and Weihai Jierui Medical Products Co., Ltd CI
ACell, Inc. and Southmedic Announce Canadian Launch of Cytal Wound Matrix and MicroMatrix CI
ACell's Gentrix Surgical Matrix Provides Exceptional Long-Term Results in Complex Patient Populations for Durable Reinforcement of Ventral Hernias CI
ACell to Host Grand Opening and Ribbon Cutting for Medical Learning Center CI
ACell, Inc. Names Nino Pionati as Vice President, International and Business Development CI
ACell, Inc. Announces Launch of Gentrix® Incisional CI
ACell, Inc. Announces New Distribution Agreement with Applied Tissue Technologies LLC CI
ACell, Inc. Announces Distribution Agreement with Southmedic, Incorporated CI
More news
Managers TitleAgeSince
Director of Finance/CFO - 31/03/13
Chief Administrative Officer - 31/12/01
Chief Tech/Sci/R&D Officer - 31/12/19
Members of the board TitleAgeSince
Director/Board Member 57 -
Director/Board Member 69 30/06/19
Director/Board Member 77 31/07/15
More insiders
ACell Inc is a United States-based company that provides wound management solutions. The Company offers a range of products, including Cytal Burn Matrix, which is a medical device used for the management of second degree burns; Cytal Wound Matrix, which is are used for acute wounds and chronic wounds; Gentrix Surgical Matrix, which is used in a range of surgical procedures, including various types of hernia repair, and MicroMatrix, which is used for acute wounds and chronic wounds. The Company uses MatriStem UBM (Urinary Bladder Matrix) technology for the manufacturing of Gentrix, Cytal, and MicroMatrix product lines.
More about the company